Anebulo Pharmaceuticals annual stock-based compensation
2021
2022
2023
2024
2025
Anebulo Pharmaceuticals Stock-Based Compensation Growth & History (ANEB)
Anebulo Pharmaceuticals's stock-based compensation was $1.4M for fiscal 2025.
View full Anebulo Pharmaceuticals company overviewAnebulo Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $1.4M | $687,940 | +90.65% |
| 2024 | 2024-06-30 | $758,884 | −$125,839 | −14.22% |
| 2023 | 2023-06-30 | $884,723 | $404,062 | +84.06% |
| 2022 | 2022-06-30 | $480,661 | $280,714 | +140.39% |
| 2021 | 2021-06-30 | $199,947 | — | — |
Anebulo Pharmaceuticals quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | $198,530 | −$365,803 | −64.82% |
| Q1 2026 | 2025-09-30 | $237,644 | −$49,276 | −17.17% |
| Q4 2025 | 2025-06-30 | $295,571 | $147,484 | +99.59% |
| Q3 2025 | 2025-03-31 | $300,000 | $100,000 | +50.00% |
| Q2 2025 | 2024-12-31 | $564,333 | $364,333 | +182.17% |
| Q1 2025 | 2024-09-30 | $286,920 | $76,123 | +36.11% |
| Q4 2024 | 2024-06-30 | $148,087 | −$124,736 | −45.72% |
| Q3 2024 | 2024-03-31 | $200,000 | $0 | 0.00% |
| Q2 2024 | 2023-12-31 | $200,000 | $0 | 0.00% |
| Q1 2024 | 2023-09-30 | $210,797 | −$1,103 | −0.52% |
| Q4 2023 | 2023-06-30 | $272,823 | $45,871 | +20.21% |
| Q3 2023 | 2023-03-31 | $200,000 | $74,746 | +59.68% |
| Q2 2023 | 2022-12-31 | $200,000 | $105,718 | +112.13% |
| Q1 2023 | 2022-09-30 | $211,900 | $177,727 | +520.08% |
| Q4 2022 | 2022-06-30 | $226,952 | $111,514 | +96.60% |
| Q3 2022 | 2022-03-31 | $125,254 | $77,847 | +164.21% |
| Q2 2022 | 2021-12-31 | $94,282 | $73,588 | +355.60% |
| Q1 2022 | 2021-09-30 | $34,173 | $17,765 | +108.27% |
| Q4 2021 | 2021-06-30 | $115,438 | — | — |
| Q3 2021 | 2021-03-31 | $47,407 | — | — |
| Q2 2021 | 2020-12-31 | $20,694 | — | — |
| Q1 2021 | 2020-09-30 | $16,408 | — | — |
Anebulo Pharmaceuticals stock-based compensation trends
Between the periods ended 2021-06-30 and 2025-06-30, Anebulo Pharmaceuticals's stock-based compensation increased from $199,947 to $1.4M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $198,530.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anebulo Pharmaceuticals source filings ↗